LEO Pharma Presents New 12-Month Real-World Data for Tralokinumab at AAD 2026

The majority of atopic dermatitis (AD) patients with hand and/or foot (H&F) involvement experienced clearance over 12 months of treatment with ADBRY(R) (tralokinumab-ldrm)/ADTRALZA(R) (tralokinumab).1 ...
Healio

Atopic dermatitis improves with tralokinumab despite atopic comorbidities

Please provide your email address to receive an email when new articles are posted on . The study included adolescents aged 12 to 17 years and adults. Comorbidities included asthma, food allergy, hay ...
The American Journal of Managed Care

FDA Approves Tralokinumab for Adolescents With Atopic Dermatitis

The human monoclonal antibody known as tralokinumab-ldrm was tested and approved as a safe, effective treatment for pediatric patients with atopic dermatitis aged 12 to 17 years old. Originally ...
Healio

Tralokinumab treatment may neutralize IL-13 in patients with atopic dermatitis

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Tralokinumab normalized expression of AD biomarkers in ...

LEO Pharma to Present 17 Scientific Abstracts at AAD 2026 Highlighting Real--World Evidence, Long--Term Outcomes and Patient Experience Across Multiple Dermatological Conditions

LEO Pharma A/S, a global leader in medical dermatology, today announced it will present 17 scientific posters at the 2026 American Academy of Dermatology (AAD) Annual Meeting (March 27-31, Denver, ...
Business Wire

LEO Pharma Announces Positive 16-Week Interim Results for ADHAND Trial for Tralokinumab in Patients with Moderate-to-Severe Atopic Dermatitis on the Hands who are Candidates ...

LEO Pharma A/S, a global leader in medical dermatology, today announced the positive results from a 16-week interim analysis of the Phase 3b ADHAND trial evaluating tralokinumab for the treatment of ...